|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ENAM |
Gene summary for ENAM |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ENAM | Gene ID | 10117 |
| Gene name | enamelin | |
| Gene Alias | ADAI | |
| Cytomap | 4q13.3 | |
| Gene Type | protein-coding | GO ID | GO:0002065 | UniProtAcc | Q9NRM1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10117 | ENAM | GSM5353216_PA_PB1A_Pool_1_3_S50_L002 | Human | Prostate | Tumor | 3.71e-02 | 5.24e-01 | 0.159 |
| 10117 | ENAM | GSM5353218_PA_PB1B_Pool_1_2_S74_L003 | Human | Prostate | Tumor | 2.46e-15 | 1.45e+00 | 0.1479 |
| 10117 | ENAM | GSM5353220_PA_PB1B_Pool_3_S51_L002 | Human | Prostate | Tumor | 3.78e-07 | 9.10e-01 | 0.1531 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ENAM | SNV | Missense_Mutation | novel | c.827N>T | p.Gly276Val | p.G276V | Q9NRM1 | protein_coding | tolerated(0.08) | probably_damaging(0.98) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| ENAM | SNV | Missense_Mutation | c.3049N>A | p.Glu1017Lys | p.E1017K | Q9NRM1 | protein_coding | deleterious(0.03) | probably_damaging(0.919) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ENAM | SNV | Missense_Mutation | novel | c.2947N>G | p.Thr983Ala | p.T983A | Q9NRM1 | protein_coding | tolerated(0.27) | benign(0.044) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| ENAM | SNV | Missense_Mutation | c.420N>T | p.Lys140Asn | p.K140N | Q9NRM1 | protein_coding | tolerated(0.18) | benign(0.027) | TCGA-D8-A1JG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| ENAM | SNV | Missense_Mutation | c.1847N>A | p.Arg616Lys | p.R616K | Q9NRM1 | protein_coding | tolerated(0.31) | benign(0.347) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ENAM | SNV | Missense_Mutation | c.2578C>G | p.Gln860Glu | p.Q860E | Q9NRM1 | protein_coding | deleterious(0.03) | possibly_damaging(0.755) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ENAM | SNV | Missense_Mutation | c.2927N>C | p.Ser976Thr | p.S976T | Q9NRM1 | protein_coding | tolerated(0.07) | benign(0.046) | TCGA-E2-A14W-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Chemotherapy | cytoxan | SD | |
| ENAM | insertion | Frame_Shift_Ins | novel | c.10_11insT | p.Arg5SerfsTer10 | p.R5Sfs*10 | Q9NRM1 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| ENAM | insertion | Frame_Shift_Ins | novel | c.3376_3377insT | p.Arg1126MetfsTer99 | p.R1126Mfs*99 | Q9NRM1 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
| ENAM | insertion | In_Frame_Ins | novel | c.3377_3378insTGCTGGTAGCTCCAC | p.Arg1126delinsSerAlaGlySerSerThr | p.R1126delinsSAGSST | Q9NRM1 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |